Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side

[thumbnail of Original article]
Preview
PDF (Original article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB

Item Type:Review
Title:Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side
Creators Name:Hudecek, M., Izsvák, Z., Johnen, S., Renner, M., Thumann, G. and Ivics, Z.
Abstract:Molecular medicine has entered a high-tech age that provides curative treatments of complex genetic diseases through genetically engineered cellular medicinal products. Their clinical implementation requires the ability to stably integrate genetic information through gene transfer vectors in a safe, effective and economically viable manner. The latest generation of Sleeping Beauty (SB) transposon vectors fulfills these requirements, and may overcome limitations associated with viral gene transfer vectors and transient non-viral gene delivery approaches that are prevalent in ongoing pre-clinical and translational research. The SB system enables high-level stable gene transfer and sustained transgene expression in multiple primary human somatic cell types, thereby representing a highly attractive gene transfer strategy for clinical use. Here we review several recent refinements of the system, including the development of optimized transposons and hyperactive SB variants, the vectorization of transposase and transposon as mRNA and DNA minicircles (MCs) to enhance performance and facilitate vector production, as well as a detailed understanding of SB's genomic integration and biosafety features. This review also provides a perspective on the regulatory framework for clinical trials of gene delivery with SB, and illustrates the path to successful clinical implementation by using, as examples, gene therapy for age-related macular degeneration (AMD) and the engineering of chimeric antigen receptor (CAR)-modified T cells in cancer immunotherapy.
Keywords:Gene Therapy Vectors, Minicircle, Eye Diseases, Chimeric Antigen Receptor, Stable Gene Transfer
Source:Critical Reviews in Biochemistry and Molecular Biology
ISSN:1040-9238
Publisher:Taylor & Francis
Volume:52
Number:4
Page Range:355-380
Date:August 2017
Additional Information:Erratum in: Crit Rev Biochem Mol Biol 52(4): i.
Official Publication:https://doi.org/10.1080/10409238.2017.1304354
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library